Certolizumab pegol

Nat Rev Drug Discov. 2008 Aug;7(8):641-2. doi: 10.1038/nrd2654.

Abstract

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.

Publication types

  • News

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized
  • Certolizumab Pegol
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / trends
  • Crohn Disease / immunology
  • Crohn Disease / metabolism
  • Crohn Disease / therapy
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • Certolizumab Pegol